Dear Reader,
From STAT’s first investigations in June 2021 revealing why the FDA gave the go-ahead for a marginally effective Alzheimer’s drug manufactured by Biogen, we have relentlessly stayed on the story. We’ve reported on the disastrous financial and leadership consequences for a one-time biopharma behemoth, as well as the dashed hopes of millions of people with dementia who had heard of a new drug called Aduhelm.